Patients' concerns regarding biological agents in rheumatology

dc.contributor.authorKimyon, Gezmiş
dc.contributor.authorZengin, Orhan
dc.contributor.authorKüçük, Adem
dc.contributor.authorŞahin, Ali
dc.contributor.authorTomas, Nazmiye
dc.contributor.authorKısacık, Bünyamin
dc.contributor.authorAkar, Servet
dc.contributor.authorOnat, Ahmet Mesut
dc.contributor.buuauthorPehlivan, Yavuz
dc.contributor.buuauthorOruçoğlu, Nurdan
dc.contributor.buuauthorPehlivan, Seda
dc.contributor.buuauthorÖksüz, Mustafa Ferhat
dc.contributor.buuauthorDalkılıç, Ediz
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Romatoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Sağlık Bilimleri Fakültesi/Hemşirelik Bölümü.tr_TR
dc.contributor.orcid0000-0002-1670-0672tr_TR
dc.contributor.orcid0000-0002-8613-5373tr_TR
dc.contributor.researcheridB-5037-2017tr_TR
dc.contributor.researcheridAAG-8227-2021tr_TR
dc.contributor.researcheridABG-1164-2020tr_TR
dc.contributor.scopusid13205593600tr_TR
dc.contributor.scopusid57199625557tr_TR
dc.contributor.scopusid23095733400tr_TR
dc.contributor.scopusid56016440100tr_TR
dc.contributor.scopusid6506739457tr_TR
dc.date.accessioned2023-11-08T10:41:07Z
dc.date.available2023-11-08T10:41:07Z
dc.date.issued2018-01
dc.description.abstractObjectiveThe potential side effects of biological agents may increase the anxiety levels of patients and influence not only their desire to use these therapies but also their concordance to treatment. This study aimed to determine the level and prevalence of drug-related concern in patients treated with biological agents and to acquire additional information regarding the related causes. Materials and MethodsA total of 1134 patients who were using biological agents for at least 3months with a diagnosis of rheumatic diseases were enrolled. General anxiety levels were evaluated using the State-Trait Anxiety Inventory (STAI). ResultsThe most common cause for drug-related concerns was the potential side effects of the drugs (59.5%). Among the potential side effects, cancer risk was the most common cause for concern (40.1%), followed by the risk of tuberculosis activation (30.7%). Anxiety levels were higher in patients who experienced side effects than in other patients, and this difference was statistically significant (P<0.05). STAI trait and state scores were moderately correlated with anxiety levels related to the drug (P<0.001). ConclusionAnxiety related to biological agents may significantly affect the patients' anxiety levels. Awareness regarding the patients' concerns and expectations related to the drug is important to ensure drug adherence and concordance to treatment.en_US
dc.identifier.citationPehlivan, Y. vd. (2018). ''Patients' concerns regarding biological agents in rheumatology''. International Journal of Rheumatic Diseases, 21(6), 1219-1226.en_US
dc.identifier.endpage1226tr_TR
dc.identifier.issn1756-1841
dc.identifier.issn1756-185X
dc.identifier.issue6tr_TR
dc.identifier.pubmed29879318tr_TR
dc.identifier.scopus2-s2.0-85048281645tr_TR
dc.identifier.startpage1219tr_TR
dc.identifier.urihttps://doi.org/10.1111/1756-185X.13319
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/1756-185X.13319
dc.identifier.urihttp://hdl.handle.net/11452/34800
dc.identifier.volume21tr_TR
dc.identifier.wos000434417500008
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalInternational Journal of Rheumatic Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectRheumatologyen_US
dc.subjectBiological agentsen_US
dc.subjectPatienten_US
dc.subjectPatients' concernen_US
dc.subjectQuality-of-lifeen_US
dc.subjectAnkylosing-spondylitisen_US
dc.subjectAnxiety disordersen_US
dc.subjectPatients wanten_US
dc.subjectDepressionen_US
dc.subjectArthritisen_US
dc.subjectInformationen_US
dc.subjectManagementen_US
dc.subjectTherapyen_US
dc.subjectCommonen_US
dc.subject.emtreeBiological producten_US
dc.subject.emtreeBiological producten_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAllergyen_US
dc.subject.emtreeAnxietyen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeCancer risken_US
dc.subject.emtreeDrug dependenceen_US
dc.subject.emtreeFearen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHeart failureen_US
dc.subject.emtreeHematologic diseaseen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfectionen_US
dc.subject.emtreeInjectionen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNeurologic diseaseen_US
dc.subject.emtreePatient worryen_US
dc.subject.emtreeReproductionen_US
dc.subject.emtreeRheumatologyen_US
dc.subject.emtreeState Trait Anxiety Inventoryen_US
dc.subject.emtreeTuberculosisen_US
dc.subject.emtreeUnspecified side effecten_US
dc.subject.emtreePatienten_US
dc.subject.emtreePsychologyen_US
dc.subject.emtreeQuestionnaireen_US
dc.subject.emtreeAnxietyen_US
dc.subject.emtreeAttitude to healthen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeEtiologyen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeMulticenter studyen_US
dc.subject.emtreeRheumatic diseaseen_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeTreatment outcomeen_US
dc.subject.emtreeTurkey (bird)en_US
dc.subject.meshAdulten_US
dc.subject.meshAnxietyen_US
dc.subject.meshBiological productsen_US
dc.subject.meshFemaleen_US
dc.subject.meshHealth knowledge, attitudes, practiceen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPatientsen_US
dc.subject.meshRheumatologyen_US
dc.subject.meshRisk ffactorsen_US
dc.subject.meshSurveys and questionnairesen_US
dc.subject.meshTreatment outcomeen_US
dc.subject.meshTurkeyen_US
dc.subject.scopusQuality Of Life; Ametantrone Diacetate; Rheumatic Diseasesen_US
dc.subject.wosRheumatologyen_US
dc.titlePatients' concerns regarding biological agents in rheumatologyen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: